230 related articles for article (PubMed ID: 18800755)
21. [Incidence of severe secondary effects during treatment with sulfonylureas and biguanides].
Berger W
Journ Annu Diabetol Hotel Dieu; 1986; ():243-53. PubMed ID: 3613372
[No Abstract] [Full Text] [Related]
22. Long-acting sulfonylureas -- long-acting hypoglycaemia.
Veitch PC; Clifton-Bligh RJ
Med J Aust; 2004 Jan; 180(2):84-5. PubMed ID: 14723592
[No Abstract] [Full Text] [Related]
23. Emergency management of oral hypoglycemic drug toxicity.
Rowden AK; Fasano CJ
Emerg Med Clin North Am; 2007 May; 25(2):347-56; abstract viii. PubMed ID: 17482024
[TBL] [Abstract][Full Text] [Related]
24. Octreotide for paediatric sulfonylurea poisonings.
Osterhoudt KC
J Paediatr Child Health; 2009; 45(7-8):473. PubMed ID: 19712185
[No Abstract] [Full Text] [Related]
25. Octreotide's role in the management of sulfonylurea-induced hypoglycemia.
Dougherty PP; Klein-Schwartz W
J Med Toxicol; 2010 Jun; 6(2):199-206. PubMed ID: 20352540
[TBL] [Abstract][Full Text] [Related]
26. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
27. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
Ragia G; Tavridou A; Elens L; Van Schaik RH; Manolopoulos VG
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):60-3. PubMed ID: 24464600
[TBL] [Abstract][Full Text] [Related]
28. Incidence of severe sideeffects during therapy with sulfonylureas and biguanides.
Berger W
Horm Metab Res Suppl; 1985; 15():111-5. PubMed ID: 3865878
[TBL] [Abstract][Full Text] [Related]
29. Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure.
Nzerue CM; Thomas J; Volcy J; Edeki T
Int J Artif Organs; 2003 Jan; 26(1):86-9. PubMed ID: 12602474
[TBL] [Abstract][Full Text] [Related]
30. [Sulfonylurea-induced hypoglycemia. An iatrogenic and potentially fatal condition].
Carlsen SM
Tidsskr Nor Laegeforen; 1997 Sep; 117(21):3079-82. PubMed ID: 9381441
[TBL] [Abstract][Full Text] [Related]
31. Octreotide as antidote for sulfonylurea-induced hypoglycemia.
Schier JG; Hirsch ON; Chu J
Ann Emerg Med; 2001 Apr; 37(4):417-8. PubMed ID: 11275841
[No Abstract] [Full Text] [Related]
32. Predictors of relapse in elderly diabetic patients admitted with sulphonylurea-induced severe hypoglycaemic attacks.
Chan TY; Cheung AY
Age Ageing; 1997 Sep; 26(5):409-10. PubMed ID: 9351488
[No Abstract] [Full Text] [Related]
33. Hypoglycemic adverse reactions to insulin and sulfonylureas.
O'Donnell J
Leg Med; 1993; ():193-232. PubMed ID: 8121229
[TBL] [Abstract][Full Text] [Related]
34. Balancing risk and benefit with oral hypoglycemic drugs.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of sulfonylurea-induced hyperinsulinemic hypoglycemia.
Graudins A; Linden CH; Ferm RP
Am J Emerg Med; 1997 Jan; 15(1):95-6. PubMed ID: 9002583
[No Abstract] [Full Text] [Related]
36. Sulfonylurea intoxication at a tertiary care paediatric hospital.
Glatstein M; Garcia-Bournissen F; Scolnik D; Koren G
Can J Clin Pharmacol; 2010; 17(1):e51-6. PubMed ID: 20124602
[TBL] [Abstract][Full Text] [Related]
37. [Hardly any hypoglycemias, constant weight--and still cost effective].
MMW Fortschr Med; 2005 Nov; 147(47):72-3. PubMed ID: 16370200
[No Abstract] [Full Text] [Related]
38. Continuous octreotide infusion for sulfonylurea-induced hypoglycemia in a toddler.
Llamado R; Czaja A; Stence N; Davidson J
J Emerg Med; 2013 Dec; 45(6):e209-13. PubMed ID: 23827165
[TBL] [Abstract][Full Text] [Related]
39. [88 severe incidents of hypoglycemia in patients under treatment with sulfonylurea compounds. Results of a survey throughout Switzerland during 1968 and 1969].
Berger W
Schweiz Med Wochenschr; 1971 Jul; 101(28):1013-22. PubMed ID: 5141777
[No Abstract] [Full Text] [Related]
40. Pasireotide (SOM230) prevents sulfonylurea-induced hypoglycemia in rats.
Schmid HA
Exp Clin Endocrinol Diabetes; 2015 Mar; 123(3):193-7. PubMed ID: 25658662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
